German doctors determine eligibility for targeted therapy by performing molecular tumor profiling to find matching genetic mutations. Specialized oncologists use biopsy-based panels and biomarker testing to identify specific proteins or markers. These precision diagnostics ensure that the selected drugs effectively attack cancer cells while sparing healthy tissue.
- Molecular profiling: Specialists use genomic sequencing to detect actionable mutations in lung or colorectal tumors.
- Biomarker analysis: Testing identifies markers like HER2-positive status to match patients with specific monoclonal antibodies.
- Histological review: Pathologists analyze tissue samples to provide detailed tumor characteristics for therapy selection.
- Multidisciplinary boards: Teams of experts review test results to create personalized treatment plans for patients.
Bookimed Expert Insight: German clinics often integrate molecular oncology research directly into patient care. For example, Dr. Séverine Iborra at the Medical Center in Solingen holds a doctorate in molecular oncology, allowing for deeper interpretation of genetic test results. Patients should look for doctors like Dr. Elke Jaeger at Nordwest Clinic, who has 35+ years of experience managing complex cases where targeted therapy is the primary focus.
Patient Consensus: Patients emphasize that eligibility depends entirely on lab results rather than cancer stage or symptoms. Many suggest asking for molecular profiling immediately to avoid delays in starting the matched drug. They also note that administrative steps occur even after a matching marker is found.
